Merck & Co. v. Reynolds
The Court ruled that investors suing Merck over its handling of Vioxx's heart-attack risks filed their lawsuit on time, because the two-year deadline for securities fraud suits does not start running until facts showing the company's fraudulent intent are discovered or reasonably should have been.
The decision clarifies, for the first time, what a federal deadline for securities-fraud suits actually requires: general warning signs about a company's problems aren't enough to start the clock -- investors also need facts pointing to deliberate wrongdoing, not just an honest mistake.
How it got here: A federal trial court dismissed the suit as too late; the Third Circuit reversed and found it timely; Merck asked the Supreme Court to resolve a split among appeals courts.
The Case in Depth
What happened
Investors sued Merck & Co., claiming the company knowingly hid heart-attack risks tied to its painkiller Vioxx while promoting a theory that a rival drug's benefits, not Vioxx's dangers, explained troubling study results. Merck argued the investors waited too long to sue, since warning signs -- a critical study, an FDA warning letter, and lawsuits accusing Merck of concealment -- appeared more than two years before the investors filed suit.
The question before the Court
When investors sue a drug company for securities fraud, does the two-year filing deadline start once red flags appear, or only once they actually discover facts showing the company meant to deceive them?
The Court's answer
No -- the deadline does not start at the first warning signs. The Court ruled that the two-year clock for filing a securities fraud lawsuit begins only once an investor actually discovers, or a reasonably diligent investor would have discovered, facts showing the company acted with fraudulent intent -- not merely facts showing a statement turned out to be inaccurate. Because fraud claims require proof of deliberate deception rather than an honest mistake, the Court reasoned that "discovery" must include facts pointing to that intent, not just red flags suggesting something might be wrong.
Applying that rule, the Court found the FDA's 2001 warning letter and related lawsuits against Merck described the company's disputed medical theory as merely "possible," without pointing to deliberate deception. Because no reasonably diligent investor would have uncovered facts showing fraudulent intent before November 2001, the investors' November 2003 lawsuit was filed on time.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Investors and companies facing securities-fraud suits nationwide now have a clearer rule for when the filing clock starts: not at the first sign of trouble, but once facts suggesting intentional wrongdoing surface. This gives investors more time to sue in complex fraud cases, while companies retain an outer five-year cutoff regardless of when fraud is uncovered.
What changes now
This is a final decision on the merits resolving a circuit split over how to read the securities-fraud filing deadline. The lawsuit against Merck may now proceed on the merits in the lower courts, since the Court held the November 2003 complaint was timely filed. The ruling also sets the standard other courts will use nationwide in future securities-fraud cases to decide when the two-year clock starts.
What this does not decide
The Court did not decide whether other elements of a securities-fraud claim -- such as facts about an investor's reliance on the misstatement, financial loss, or the connection between the loss and the fraud -- must also be discovered before the filing clock starts. It also declined to say whether a later 2003 study might separately have triggered the deadline.
Concurrences and dissents
Concurrence — Justice Stevens
Justice Stevens agreed the complaint was timely and joined the Court's opinion, but noted that in this case there was no actual difference between when the investors truly discovered the fraud and when a reasonably diligent investor would have discovered it. He would therefore reserve judgment on whether the deadline should turn on actual versus constructive discovery until a case where that distinction actually matters.
Concurrence — Justice Scalia
Justice Scalia agreed that fraudulent intent must be discovered and that the suit was timely, but for a different reason: he would hold that only a plaintiff's actual discovery of fraud starts the clock, not what a reasonably diligent plaintiff should have found. He reasoned that a related securities statute explicitly includes a 'reasonable diligence' standard while this one does not, showing Congress meant something narrower here.
How the Court got there
The legal reasoning, step by step
- The Court read the phrase 'discovery of the facts constituting the violation' in the federal securities-fraud filing deadline as embodying the traditional discovery rule -- a doctrine that delays the start of a lawsuit's clock until the plaintiff either actually learns the relevant facts or a reasonably diligent plaintiff would have learned them.
- The Court concluded that a defendant's fraudulent intent, known as scienter -- a mental state involving intent to deceive rather than an innocent mistake -- counts as one of the 'facts constituting the violation,' because a securities fraud claim cannot succeed without proving the defendant acted with that intent.
- Because heightened pleading rules require a fraud complaint to show it is at least as likely as not that the defendant acted with fraudulent intent, the Court reasoned that the filing clock cannot start until facts pointing to that intent are discovered, not merely facts showing a statement turned out to be false.
- The Court rejected Merck's proposed 'inquiry notice' standard -- starting the clock whenever facts would prompt a reasonable investor to investigate further -- because that earlier point does not necessarily mean the investor has yet discovered facts showing fraudulent intent.
- Applying this standard, the Court found that the pre-November 2001 events, including the FDA's warning letter and the products-liability lawsuits, described Merck's alternative explanation as merely 'possible' rather than pointing to deliberate deception, so no reasonably diligent investor would have uncovered the necessary facts about intent before that date.
Doctrinal impact
Cases affected by this decision
Reaffirms Lampf, Pleva, Lipkind, Prupis & Petigrow v. Gilbertson (501 U. S. 350)
The Court relied on Lampf's earlier language about discovering fraud facts to interpret the current statute's wording.